STOCK TITAN

Amgen (NASDAQ: AMGN) SVP receives RSU grant and 3,167 stock options

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Amgen SVP & CCO Nancy A. Grygiel reported routine equity compensation activity. She received 485 shares of common stock as a grant, increasing her direct holdings to 7,494 shares, and was granted 3,167 non-qualified stock options at $329.59 per share, vesting in four annual installments starting on May 5, 2027.

The filing also shows 76 shares were withheld at $329.59 per share to cover tax obligations, leaving 7,418 directly held shares afterward. The stock grant consists of Restricted Stock Units that convert one-for-one into common shares as they vest, and the options are exercisable in equal parts through May 5, 2030 with an expiration on May 5, 2036. An indirect 401(k) holding of 106.1864 shares is also reported.

Positive

  • None.

Negative

  • None.
Insider Grygiel Nancy A.
Role SVP & CCO
Type Security Shares Price Value
Tax Withholding Common Stock 76 $329.59 $25K
Grant/Award Nqso (Right to Buy) 3,167 $329.59 $1.04M
Grant/Award Common Stock 485 $0.00 --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 7,418 shares (Direct, null); Nqso (Right to Buy) — 6,334 shares (Direct, null); Common Stock — 106.186 shares (Indirect, 401(k) Plan)
Footnotes (1)
  1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. These shares include 68 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027.
RSU share grant 485 shares Restricted Stock Units vesting in four annual installments from May 5, 2027
Non-qualified stock options granted 3,167 options at $329.59 Exercise price and size of new option grant on May 5, 2026
Direct shares after grant 7,494 shares Total directly held common shares following the 485-share award
Direct shares after tax withholding 7,418 shares Direct holdings after 76 shares were withheld for taxes
Tax withholding shares 76 shares at $329.59 Shares delivered to cover tax liabilities on May 6, 2026
Option vesting start date May 5, 2027 First vesting date for non-qualified stock options
Option expiration date May 5, 2036 Final expiration date for the non-qualified stock options
Indirect 401(k) holdings 106.1864 shares Common stock held indirectly through a 401(k) plan
Restricted Stock Units (RSUs) financial
"The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc."
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
Dividend Equivalents (DEs) financial
"These shares include 68 Dividend Equivalents (DEs) granted pursuant to the Equity"
non-qualified stock options financial
"These non-qualified stock options were granted pursuant to the Equity Incentive Plan"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
Equity Incentive Plan financial
"granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
Dividend Equivalents financial
"DEs are credited to the reporting person's unvested Restricted Stock Units"
Payments tied to employee or contractor equity awards that mirror the cash dividends paid on the company’s stock; they give the holder the same economic benefit as owning the shares without transferring actual shares—often paid in cash or additional award units when the award becomes payable. Investors care because these payments affect a company’s compensation costs, cash flow and potential share dilution, and they signal how management is being rewarded and aligned with shareholders.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Grygiel Nancy A.

(Last)(First)(Middle)
ONE AMGEN CENTER DRIVE

(Street)
THOUSAND OAKS CALIFORNIA 91320

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SVP & CCO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/05/2026A485(1)A$07,494D
Common Stock05/06/2026F76D$329.597,418(2)D
Common Stock106.1864I401(k) Plan
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Nqso (Right to Buy)$329.5905/05/2026A3,16705/05/2027(3)05/05/2036Common Stock3,167$329.596,334D
Explanation of Responses:
1. The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Equity Incentive Plan) and vest in four equal annual installments of 25% each, commencing on 5/5/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
2. These shares include 68 Dividend Equivalents (DEs) granted pursuant to the Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
3. These non-qualified stock options were granted pursuant to the Equity Incentive Plan and vest and are exercisable in four equal annual installments of 25% each, commencing on 5/5/2027.
/s/ Nancy A. Grygiel05/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Amgen (AMGN) grant to Nancy A. Grygiel in this Form 4?

Nancy A. Grygiel received a grant of 485 shares of Amgen common stock and 3,167 non-qualified stock options at $329.59 per share. Both awards vest in four equal annual installments beginning May 5, 2027, providing staged long-term equity compensation.

How do the Restricted Stock Units in the Amgen (AMGN) Form 4 vest and settle?

The Restricted Stock Units vest in four equal annual installments of 25% each starting May 5, 2027. Once vested, each RSU is paid out in one share of Amgen common stock, aligning compensation with future company performance over several years.

What are the terms of the non-qualified stock options reported for Amgen (AMGN)?

The Form 4 shows 3,167 non-qualified stock options with a $329.59 exercise price. These options vest and become exercisable in four equal annual installments beginning May 5, 2027, and expire on May 5, 2036, offering long-dated equity upside potential.

Why were 76 Amgen (AMGN) shares disposed of in Nancy Grygiel’s Form 4?

The 76 shares were withheld at $329.59 per share to satisfy tax liabilities related to equity awards. This F-code transaction is a tax-withholding disposition, not an open-market sale, and is a common administrative step when stock-based compensation vests or is granted.

What indirect Amgen (AMGN) ownership is reported in Nancy Grygiel’s Form 4?

The filing reports 106.1864 Amgen common shares held indirectly through a 401(k) plan. This reflects retirement-plan holdings rather than directly held stock certificates, providing additional equity exposure alongside her directly owned shares and granted awards.